Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
In the latest session, Novartis AG ADR (NYSE: NVS) closed at $121.2 up 1.58% from its previous closing price of $119.31. In other words, the price has increased by $1.58 from its previous closing price. On the day, 1.09 million shares were traded. NVS stock price reached its highest trading level at $121.55 during the session, while it also had its lowest trading level at $120.0.
Ratios:
For a deeper understanding of Novartis AG ADR’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 32.86 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 11.84. For the most recent quarter (mrq), Quick Ratio is recorded 0.62 and its Current Ratio is at 0.82. In the meantime, Its Debt-to-Equity ratio is 0.78 whereas as Long-Term Debt/Eq ratio is at 0.57.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 23 ’25 when Marshall Fiona bought 15,000 shares for $112.68 per share.
Kowalski Robert William bought 1,212 shares of NVS for $137,297 on Apr 30 ’25.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NVS now has a Market Capitalization of 234625007616 and an Enterprise Value of 256940638208. As of this moment, Novartis’s Price-to-Earnings (P/E) ratio for their current fiscal year is 17.55, and their Forward P/E ratio for the next fiscal year is 13.11. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.22. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.30 while its Price-to-Book (P/B) ratio in mrq is 5.59. Its current Enterprise Value per Revenue stands at 4.656 whereas that against EBITDA is 10.91.
Stock Price History:
The Beta on a monthly basis for NVS is 0.62, which has changed by 0.069631934 over the last 52 weeks, in comparison to a change of 0.16657472 over the same period for the S&P500. Over the past 52 weeks, NVS has reached a high of $124.83, while it has fallen to a 52-week low of $96.06. The 50-Day Moving Average of the stock is 2.40%, while the 200-Day Moving Average is calculated to be 10.61%.
Shares Statistics:
For the past three months, NVS has traded an average of 1.62M shares per day and 1736600 over the past ten days. A total of 1.94B shares are outstanding, with a floating share count of 1.90B. Insiders hold about 0.00% of the company’s shares, while institutions hold 7.36% stake in the company. Shares short for NVS as of 1753920000 were 4377907 with a Short Ratio of 2.71, compared to 1751241600 on 4060960. Therefore, it implies a Short% of Shares Outstanding of 4377907 and a Short% of Float of 0.22999999999999998.
Dividends & Splits
According to the company, the forward annual dividend rate for NVS is 3.87, from 3.862 in the trailing year. Against a Trailing Annual Dividend Yield of 0.032369457The stock’s 5-year Average Dividend Yield is 3.63. The current Payout Ratio is 55.42% for NVS, which recently paid a dividend on 2025-03-12 with an ex-dividend date of 2025-03-12. Stock splits for the company last occurred on 2019-04-09 when the company split stock in a 1116:1000 ratio.
Earnings Estimates
Novartis AG ADR (NVS) is currently under the scrutiny of 2.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is $2.02, with high estimates of $2.03 and low estimates of $2.01.
Analysts are recommending an EPS of between $9.26 and $8.71 for the fiscal current year, implying an average EPS of $9.02. EPS for the following year is $9.31, with 8.0 analysts recommending between $9.89 and $8.95.
Revenue Estimates
A total of 4 analysts believe the company’s revenue will be $13.69B this quarter.It ranges from a high estimate of $13.91B to a low estimate of $13.38B. As of the current estimate, Novartis AG ADR’s year-ago sales were $12.82BFor the next quarter, 4 analysts are estimating revenue of $13.58B. There is a high estimate of $13.96B for the next quarter, whereas the lowest estimate is $13.04B.
A total of 15 analysts have provided revenue estimates for NVS’s current fiscal year. The highest revenue estimate was $57.96B, while the lowest revenue estimate was $52.72B, resulting in an average revenue estimate of $54.97B. In the same quarter a year ago, actual revenue was $50.32BBased on 15 analysts’ estimates, the company’s revenue will be $56.19B in the next fiscal year. The high estimate is $60.66B and the low estimate is $52.52B.
